Trial Profile
Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms FTY720
- Sponsors Novartis
- 09 May 2017 Status changed from completed to discontinued.
- 09 May 2017 Status changed from completed to discontinued.
- 16 Feb 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.